Marquette Asset Management LLC Invests $621,000 in Fulgent Genetics, Inc. $FLGT

Marquette Asset Management LLC acquired a new position in Fulgent Genetics, Inc. (NASDAQ:FLGT) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 30,269 shares of the company’s stock, valued at approximately $621,000.

A number of other institutional investors and hedge funds have also bought and sold shares of FLGT. Y Intercept Hong Kong Ltd acquired a new position in Fulgent Genetics during the 1st quarter worth about $1,076,000. Northwestern Mutual Wealth Management Co. grew its position in shares of Fulgent Genetics by 2,984,354.9% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,522,072 shares of the company’s stock valued at $39,985,000 after buying an additional 1,522,021 shares during the last quarter. Levin Capital Strategies L.P. acquired a new stake in shares of Fulgent Genetics in the first quarter valued at about $687,000. Public Employees Retirement System of Ohio raised its position in shares of Fulgent Genetics by 3,217.5% during the first quarter. Public Employees Retirement System of Ohio now owns 33,739 shares of the company’s stock worth $536,000 after acquiring an additional 32,722 shares during the last quarter. Finally, UBS Group AG raised its position in shares of Fulgent Genetics by 288.8% during the fourth quarter. UBS Group AG now owns 83,559 shares of the company’s stock worth $2,195,000 after acquiring an additional 62,070 shares during the last quarter. 48.06% of the stock is currently owned by institutional investors and hedge funds.

Fulgent Genetics Price Performance

Shares of NASDAQ FLGT opened at $19.06 on Tuesday. The stock has a market capitalization of $524.34 million, a P/E ratio of -6.76 and a beta of 0.91. The company has a 50-day moving average price of $19.39 and a 200-day moving average price of $18.78. Fulgent Genetics, Inc. has a 1 year low of $13.46 and a 1 year high of $31.04.

Fulgent Genetics (NASDAQ:FLGT) last posted its earnings results on Thursday, July 30th. The company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.12). Fulgent Genetics had a negative return on equity of 4.93% and a negative net margin of 26.05%.The business had revenue of $85.39 million during the quarter, compared to analyst estimates of $94.00 million. Fulgent Genetics has set its FY 2026 guidance at -2.350–2.220 EPS. As a group, equities research analysts anticipate that Fulgent Genetics, Inc. will post -2.81 earnings per share for the current fiscal year.

Analyst Ratings Changes

FLGT has been the topic of a number of research analyst reports. Wall Street Zen cut shares of Fulgent Genetics from a “sell” rating to a “strong sell” rating in a research report on Saturday. Piper Sandler lifted their price objective on Fulgent Genetics from $15.00 to $19.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 4th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Fulgent Genetics in a research note on Monday, July 6th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $27.50.

Insider Activity at Fulgent Genetics

In related news, COO Jian Xie sold 2,146 shares of Fulgent Genetics stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $17.89, for a total transaction of $38,391.94. Following the transaction, the chief operating officer owned 367,605 shares of the company’s stock, valued at $6,576,453.45. The trade was a 0.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Hanlin Gao sold 1,688 shares of the company’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $17.89, for a total value of $30,198.32. Following the sale, the insider owned 990,374 shares of the company’s stock, valued at $17,717,790.86. This trade represents a 0.17% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 5,980 shares of company stock valued at $106,360. Company insiders own 36.18% of the company’s stock.

About Fulgent Genetics

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.